NCT01001442 · MORE INFO

Limitations, agreements, and source contact

Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma · Source last updated 2019-07-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

other Details: Part of CTA:The Investigator or any Site employee, consultant or admitting physician to the Site or Study Team member is not allowed to make any publication of any Study Data, information, results, or similar information without the review and comment of SPONSOR. As the Study is part of a multi-center trial, and the Investigator/site agree that no publication by Site/Investigator of the results of the Study conducted at the Site shall be made before the first multi-centre publication.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

point Of Contact

Complete source fields

certain Agreement

other Details: Part of CTA:The Investigator or any Site employee, consultant or admitting physician to the Site or Study Team member is not allowed to make any publication of any Study Data, information, results, or similar information without the review and comment of SPONSOR. As the Study is part of a multi-center trial, and the Investigator/site agree that no publication by Site/Investigator of the results of the Study conducted at the Site shall be made before the first multi-centre publication.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

point Of Contact

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice